Yet, the molecular mechanism(s) of RPC are still unclear.
S
troke is a leading cause of death and long-term disability 1 with no clinically approved neuroprotective treatments. Although translation of therapies that target deleterious mechanisms postinjury has been challenging, the field of preconditioning offers an additional therapeutic window and novel targets for significant neuroprotection. Our laboratory and others have demonstrated the efficacy of preconditioning with resveratrol (resveratrol preconditioning, RPC), a naturally occurring polyphenolic compound.
2,3 RPC-induced ischemic tolerance is observed at both early (24 hours) and late (>1 week) time points postinjury, with validation across species, age, sex, and models of cerebral ischemia including neonatal hypoxia-ischemia, ischemic stroke, recurrent stroke, and asphyxial cardiac arrest. [3] [4] [5] [6] Stroke November 2017
and has been implicated in the regulation of inflammation, 10 cerebral blood flow, 11 and neuronal functions. 12 It remains to be tested whether SIRT1 is essential for RPC-induced ischemic tolerance and if so, in which cell types. These are important discrepancies to reconcile regarding translation of novel therapies.
SIRT1 is an nicotinamide adenine dinucleotide-dependent deacetylase that acts on histone and nonhistone proteins to induce adaptive responses to metabolic stress. 13 These responses are extensively characterized in peripheral tissues, where SIRT1 mediates a switch from anabolic to catabolic processes, promotes the utilization of alternative energy substrates, and regulates systemic glucose output. 13 The brain, however, may lack this metabolic plasticity given its tight regulation of energy metabolism. While SIRT1 controls neuroendocrine function at the organismal level from within hypothalamic nuclei, 13 it is still unclear how SIRT1 regulates metabolism at the cellular level in the brain and particularly neurons. This regulation is likely essential for the maintenance of neuronal function, within normal physiology and disease.
The aim of this study was to determine if specifically neuronal SIRT1 is necessary for RPC-induced ischemic tolerance and to identify the potential metabolic pathways through which SIRT1 exerts neuroprotection at the cellular level in the brain. To this end, we used a conditional and inducible genetic approach to delete Sirt1 specifically in adult neurons and subjected mice to transient ischemic stroke. Furthermore, we conducted metabolomics analysis of control and neuronal Sirt1 knockout mice to identify putative metabolic pathways regulated by neuronal SIRT1 in brain. Finally, we assessed the neuroprotective potential of SIRT1-mediated enhancement of neuronal glycolysis induced by RPC. ) mice. Eightto 12-week-old male mice (≈20-25 g) were used throughout to eliminate the influence of estrous cycle on ischemic injury. Induction was achieved by IP tamoxifen (0.13 mg/g, Sigma, St. Louis, MO) injections 1× per day for 5 days followed by 5 days of rest.
Materials and Methods

Generation of
Transient Middle Cerebral Artery Occlusion
RPC was induced by treatment with transresveratrol (3,4′,5-trihydroxytrans-stilbene, 10 mg/kg (Sigma) in 1.5% DMSO) or vehicle (1.5% DMSO) IP, 2 days before transient middle cerebral artery occlusion (tMCAo) performed as described previously. 12 Mice were anesthetized with 3% isoflurane in 100% O 2 and maintained at 37.0°C through a rectal monitoring heating pad (Harvard Apparatus, Holliston, MA). tMCAo was induced by insertion of a silicone-coated 8-0 monofilament surgical suture (Doccol, Sharon, MA) into the MCA. After 60 minutes, the suture was removed. Cerebral blood flow was measured before, during, and immediately after tMCAo using a Laser-Doppler (Perimed System, Stockholm, Sweden) probe. Animals that did not display a ≥70% reduction in cerebral blood flow during occlusion were excluded.
Neurological Scoring
Twenty-four hours after tMCAo, animals were scored based on a neurobehavioral battery (body symmetry, gait, climbing, circling behavior, forelimb symmetry, compulsory circling, and whisker response) as described previously. 12 Focal score ranges from 0 to 28, where 0 is considered normal and 28 indicates extremely severe deficits.
Quantification of Infarct Volume
Triphenyl tetrazolium chloride (Sigma) staining for infarct was performed as described previously. 12 Infarcted area and total ipsilateral area were measured using ImageJ software, and infarct was calculated as a percentage of the total ipsilateral hemisphere.
Nontargeted Primary Metabolomics
Sample preparation, data acquisition, and data processing was performed by the West Coast Metabolomics Center (UC-Davis) as described previously.
14 This nontargeted primary metabolism platform was achieved by gas chromatography-time of flight-mass spectrometry. See the online-only Data Supplement.
Metabolomics Statistical and Biochemical Analysis
Peak intensity values normalized to tissue weight were used for statistical analysis in MetaboAnalyst 3.0 15 (n=7-8) . One sample was a statistical outlier (Random Forest outlier detection, largest outlying measure >3.0) and was removed from analysis. Values were log transformed and auto scaled. Networks that display structural similarity of metabolites based on PubChem substructure fingerprints were generated by MetaMapR 16 and visualized in Cytoscape.
Acute Brain Slice Preparation
Adult (≈20-25 g) mice were anesthetized with 2% isoflurane and their brains were cubed for sagittal sectioning. 
Extracellular Field Recordings and Anoxic Depolarization
Field population spikes were recorded in the pyramidal cell body layer of Cornu Ammonis hippocampus with NaCl-filled (150 mmol/L) micropipettes. Schaffer collateral axons were electrically stimulated by 0.3 ms constant current pulses at half-maximal response (from input-output curve) and excluded if they displayed double fSpike properties, indicative of poor slice health. For anoxic depolarization (AD) experiments, extracellular recording monitored the onset of a direct current shift, while Schaffer collaterals were stimulated every 15 seconds to monitor field population spikes . Baseline was recorded for 5 minutes in normal aCSF (see above) before experimental conditions of aCSF with no glucose or aCSF with glucose (20 mmol/L). Anoxia was induced by bubbling with 95% N, 5% CO 2 and deoxygenating slices with humidified 95% N, 5% CO 2 . Latency until AD was defined as the rate of direct current shift exceeding 10 V/s.
Primary Neuronal-Enriched Cultures
Primary neuronal-enriched cultures were prepared as described previously, 17 with some modifications. Pregnant female Sprague-Dawley rats (E18-19) were acquired from Charles River (Wilmington, MA). Pups were harvested, their cortical tissue was homogenized, dissociated, and washed with neuronal media (minimum essential media, 1% Glutamax, 10% fetal bovine serum, and 20 mmol/L glucose). Cells were plated at a density of 80 000 cells per Seahorse Extracellular Flux Analyzer Miniplate well (Aligent, Santa Clara, CA). Cultures underwent half media changes every third day for 7 to 10 days before experimentation.
Glycolytic Rate In Vitro
Glycolytic rate was measured using the Seahorse Extracellular Flux Analyzer Analyzer (Aligent) according to the manufacturer's instructions and published standards. 18 Neurons were treated with resveratrol (100 µmol/L, 1.5% DMSO), vehicle (1.5% DMSO), or the Sirt1 specific-inhibitor EX-527 (Sigma, 1 µM, 10 µM) 2 days before measurements. On the day of measurements, neurons were washed 3× with seahorse media (XF Base Medium-Minimum Dulbecco's Modified Eagle's Medium, 20 mmol/L glucose, 1 mmol/L sodium pyruvate, and 2 mmol/L glutamine) and incubated in a CO 2 -free incubator at 37°C for 1 hour before plate run. Extracellular acidification rate was normalized to cell count in a reference well.
Western Blot, Immunofluorescence and Real-Time Polymerase Chain Reaction
For these standard methods, refer to the online-only Data Supplement. The information about the primers and antibodies used are found in Table IV in the online-only Data Supplement.
Statistical Analysis and Blinding Procedures
Mice were randomly assigned groups throughout. Data acquisition and analyses were conducted in a blinded manner. Statistical analysis was performed in Prism6 software (GraphPad, San Diego, CA). Data are presented as mean±SEM. Two-sample, unpaired Student t test, 1-and 2-way ANOVA with Bonferroni post hoc tests, and repeated measures 2-way ANOVA with Bonferroni post hoc tests were used as indicated in the text and figure legends. Significance is denoted in each figure. Sample size was determined for each experiment depending on prior experiments conducted by the laboratory and power analysis to detect an effect size of 0.8 using G*power 3.1 software. Statistical tests meet necessary assumptions as measured in Prism6.
Results
Generation of Inducible, NeuronalSpecific Sirt1 Knockout Mice
To specifically investigate postdevelopmental neuronal SIRT1 function, we generated tamoxifen-inducible, neuronal-specific Sirt1 knockout mice. Single-neuron labeling inducible Cremediated knockout mice, 19 where creER T2 and EYFP are under control of the pan-neuronal promoter Thy1.2, were crossed with Sirt1 flox/flox mice that harbor loxP sites flanking the catalytic domain (exon 4) of Sirt1. 20 In these mice (Sirt1
), tamoxifen treatment results in deletion of exon 4 from Sirt1 exclusively in neurons, rendering a mutant protein that lacks deacetylase activity. 20 Sirt1 neu−/− exhibit strong EYFP fluorescence throughout major brain regions ( Figure 1A ). EYFP did not show robust expression in the hypothalamus, and body weight was unchanged 1 week after induction ( Figure I in the online-only Data Supplement), suggesting that SIRT1 regulation of systemic metabolism from the hypothalamus is not overtly altered. Immunostaining revealed colocalization of EYFP and the neuronal marker NeuN ( Figure 1B) but not the glial marker glial fibrillary acidic protein ( Figure 1C) , demonstrating neuronal specificity. In noninduced mice, SIRT1 is primarily neuronal, colocalizing with EYFP and NeuN but not glial fibrillary acidic protein ( Figure 1A and 1C) . Efficiency of Sirt1 deletion was assessed by Western blot, where full-length wild-type SIRT1 is observed as 2 bands at 110 kDa. In Sirt1 neu−/− , these bands were observed at a lower molecular weight, indicating truncation of SIRT1 protein, which now lacks exon 4 ( Figure 1D ). No mutant SIRT1 or EYFP protein was found in other tissues, such as heart ( Figure 1D ; Figure II in (Figure 2A and 2B) . Cerebral blood flow measurements during ischemia or at the onset of reperfusion did not differ between groups ( Figure 2C ), demonstrating that these results were not because of changes in cerebral perfusion. These data show that RPC-induced ischemic tolerance requires neuronal SIRT1.
Glucose and Purine Metabolism Are Altered in Sirt1 neu−/− Mouse Brain
Because neuronal SIRT1 is necessary for RPC-induced ischemic tolerance, we sought to identify the cellular metabolic pathways of SIRT1 in neurons, which remain largely unknown. To this end, we generated nontargeted primary metabolite profiles from naive control and Sirt1 neu−/− hippocampi (most efficient Sirt1 deletion, Figure III in the onlineonly Data Supplement) under basal conditions. In total, 227 peaks were captured, 115 of which were structurally annotated metabolites. Statistical analysis using MetaboAnalyst found 23 metabolites significantly altered in Sirt1 neu−/− (P<0.05, false discovery rate <0.2; Table) . Full lists of measured metabolites and metrics are located in Tables II and III in the online-only Data Supplement. Structural similarity networks revealed that the majority were carbohydrates or purines related to glucose metabolism ( Figure 3A ). Metabolites associated with ATP consuming processes of glucose and its derivatives were more abundant and included those in glycolysis (early stepsglucose, glucose 6-phosphate, fructose 6-phosphate, and fructose 1,6-bisphosphate), pentose phosphate pathway, and downstream purines (ribitol, inosine monophosphate, inosine, guanosine, adenine, and xanthine) and complex carbohydrates (mannose). These changes were concomitant with increased expression of the GLUT1 (glucose transporter, 38 (Figure 3B and 3C ). These data indicate more flux through the initial steps of glycolysis and the pentose phosphate pathway. Interestingly, 3-phosphoglycerate, a metabolite associated with the first ATP producing step in glycolysis, and serine, which can be interconverted to 3-phosphoglycerate, were less abundant, suggesting that glucose is diverted to branch point pathways and exits glycolysis before its complete oxidation. To determine the involvement of transcription factors that regulate glucose metabolism, we measured expression of hypoxia-inducible factor-1 alpha (HIF-1α), a known target of SIRT1, 22 and 2 other sirtuins shown to regulate glycolysis. While Hif-1α (41.7%, P<0.01) expression was increased in Sirt1 neu−/− , Sirt2 and Sirt6 had similar expression levels ( Figure 3D ). Together, these data show that neuronal SIRT1 regulates glucose metabolism in the brain.
Glycolytic ATP Production Is Impaired in Sirt1 neu−/− Mouse Brain
Given that the initial steps of glycolysis, purine synthesis, and synthesis of complex carbohydrates, are all ATP consuming processes, we hypothesized that in Sirt1 neu−/− glucose is being preferentially diverted to these ATP consuming pathways rather than being fully oxidized as an energy substrate. To test glycolytic ATP production, we measured latency until AD as a readout of glycolytic function. Studies show that when mitochondria are inhibited by anoxia, glucose can extend latency to AD through glycolytic ATP production. 23 We measured AD latency by extracellular field recording in the hippocampal Cornu Ammonis region of acute brain slices. Gross synaptic transmission did not differ between control and Sirt1 neu−/− slices, evidenced by similar evoked field population spike amplitudes ( Figure 4A ) and expression of Na + /K + ATPase subunits ( Figure IV in the online-only Data Supplement). Latency to AD under anoxia and perfusion of aCSF with no glucose was similar between control and Sirt1 neu−/− (control-3.60 minutes, Sirt1 neu−/− -3.36 minutes, Figure 4B ). In controls, perfusion with 20 mmol/L glucose aCSF under anoxia significantly extended latency to AD (8.31 minutes, P<0.001), suggesting normal glycolytic ATP production that contributes substantially to AD latency. The glycolysis inhibitor iodoacetate abolished the extended latency to AD with 20 mmol/L glucose in control (1.74 minutes, P<0.001), confirming that this effect is mediated through glycolysis. In Sirt1 neu−/− , however, perfusion with 20 mmol/L glucose aCSF failed to extend latency to AD, indicating impaired glycolytic ATP production compared with control ( Figure 4B ). Together, these data suggest that neuronal SIRT1 promotes glycolytic ATP production. 
RPC Increases Glycolytic Rate in Neurons in a Sirt1-Dependent Manner
Next, we postulated that SIRT1 positively regulates glycolysis as an energy pathway in brain. To this end, we measured glycolytic rate in rat primary neuronal-enriched cultures using the Seahorse Extracellular Flux Analyzer and inhibited SIRT1 pharmacologically given the low deletion efficiency of inducible cre/lox systems in vitro and to avoid any confounding effects of tamoxifen. Under basal conditions, inhibition of Sirt1 with the specific-inhibitor EX-527 (10 µmol/L) for 2 days before measurements modestly reduced (12.1%, P<0.01) glycolytic rate. EX-527 also inhibited maximal glycolytic rate Figure 5A ). Inhibition of Sirt1 at the time of RPC treatment significantly reduced these increases (basal-12.1%, P<0.05; maximal-10.1%, P<0.01), demonstrating the SIRT1-dependence of these effects ( Figure 5A ).
Enhanced glycolytic function could be important in ischemic penumbra, where energy substrates are significantly decreased but still present. Thus, we tested whether these RPC-induced changes in glycolytic rate occur under conditions of low glucose and mitochondrial dysfunction. Indeed, when cells were exposed to 25% of normal glucose (5 mmol/L glucose instead of 20 mmol/L) and mitochondria were inhibited, glycolytic rate was increased in RPC neurons (16.6%, P<0.001; Figure 5B ). Together, these data demonstrate that RPC increases glycolytic rate in neurons through SIRT1, an effect that was evident in ischemic conditions.
Discussion
Although the efficacy of resveratrol is demonstrated across species, sex, age, and models of cerebral ischemia, its mechanism(s) are not well understood spatially and temporally. Studies indicate that modulation of both systemic processes and brain or neuronal functions can afford robust protection. What is more, the Sirt1-dependence of resveratrol-elicited protection has not been investigated fully. Here, we found that RPC-induced 
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protection is lost in the absence of neuronal SIRT1, demonstrating a robust mechanism that either originates or terminates in neurons. Importantly, cerebral blood flow during ischemia or at the onset of reperfusion was unaffected by deletion of neuronal SIRT1 or RPC. Still, SIRT1 promotes angiogenesis through the migration and sprouting of endothelial cells 24 and can maintain cerebral blood flow through deacetylation of endothelial nitric oxide synthase. 11 Mice overexpressing Sirt1 are resistant to global ischemia by retaining cerebral perfusion up to 45% to 50% of baseline. 25 Moreover, resveratrol elicits proangiogenic effects in brain endothelial cells through mitogen-activated protein kinase signaling and upregulation of endothelial nitric oxide synthase. 7 Our data indicate that neuronal activities of SIRT1 take precedence over RPC-induced ischemic tolerance, most likely orchestrating and acting in concert with systemic and non-neuronal effects. This conclusion is supported by several studies that implicate neuronal function in RPC. 4, 8, 9, 12 The temporal distribution of resveratrol-elicited effects is also a probable factor in determining their precedence and warrants further investigation. Interestingly, Sirt1 neu−/− mice displayed similar infarct sizes and neurological scores compared with control mice, indicating a negligible innate role for neuronal SIRT1 in focal ischemic injury. In line with this finding, mice overexpressing Sirt1 specifically in neurons were not protected from tMCAo, evidenced by infarct size and functional outcome comparable with wild-type mice. 26 However, Sirt1 null mice are more susceptible to permanent MCAo, 27 and mice that constitutively overexpress Sirt1 in all tissues are resistant to bilateral common carotid artery occlusion, 25 a model of global ischemia, suggesting that SIRT1 does contribute to endogenous ischemic neuroprotection. This discrepancy likely stems from several factors that make comparison across these studies difficult: 3 different ischemia models were used (transient and permanent MCAo, global ischemia) that have different pathophysiology, injury severity ranged from mild to severe across these models, outcome measures were evaluated at different time points postischemia, and constitutive Sirt1 null mice have neurodevelopmental defects that may confound results. A detailed assessment of neuroprotection in Sirt1 neu−/− mice with titrated injury severity and long-term recovery will more accurately evaluate the innate role of neuronal SIRT1.
In the current study, we identify a novel role for neuronal SIRT1 in the regulation of brain glycolysis. In liver, under metabolic stress, SIRT1 and PGC-1α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha) work in concert to suppress glycolytic genes (glucokinase, pyruvate kinase), promote gluconeogenic genes and ultimately the production of glucose. 28 Our results suggest that in the brains of Sirt1 neu−/− mice, PGC-1α activity might not be altered because expression of its target gene pyruvate kinase was unchanged. However, we observed increases in expression of the Hif-1α target genes Glut1, hexokinase 2, and phosphofructokinase. In line with this result, SIRT1 and HIF-1α are known to interact in brain, where SIRT1-mediated deacetylation of HIF-1α at Lys674 inactivates it and represses its target glycolytic genes. 22 Alternatively, PGC-1α and another well-characterized target of Sirt1 deacetylation, p53, regulate mitochondrial metabolic pathways. Pgc-1α null mouse brains have decreased expression of oxidative genes, 29 and p53 is involved in various aspects of mitochondrial quality control. 30 However, Sirt1 neu−/− mice did not display alterations in mitochondria-associated metabolites, such as tricarboxylic acid cycle intermediates or 
November 2017 fatty acids, suggesting that these SIRT1 targets may be less robust in brain or have compensatory regulation in the absence of neuronal SIRT1. Still, several purine metabolites were significantly increased in Sirt1 neu−/− and could reflect a more subtle defect in mitochondrial metabolism because many of the rate-limiting and ATP-dependent reactions for purines are localized to mitochondria. 31 More specific experiments concerning the effects of neuronal Sirt1 deletion on mitochondrial bioenergetics are needed to address this issue.
In contrast to peripheral tissues, the brain relies heavily on glucose for energy production and thus SIRT1 regulation of glycolysis may differ in this tissue. Whereas SIRT1 deficiency increases glycolytic activity in T helper 9 cells, 32 we found that RPC increases glycolytic rate in a SIRT1-dependent manner in neurons, demonstrating a cell-type-specific function. Although the bulk of brain ATP is generated from the oxidation of pyruvate within mitochondria, recent studies highlight the importance of neuronal glycolysis. Local production of ATP from glycolysis is crucial for fast axonal transport of vesicles, 33 the energetic demand of action potential firing, 34 and the maintenance of synaptic ATP levels under energetic stress. 35 Our results demonstrate that under mitochondrial stress by anoxia, glycolysis can produce a significant amount of ATP to maintain ion gradients and delay depolarization, an effect that was lost with deletion of neuronal Sirt1. Moreover, studies show that the Na + /K + ATPase, which is a main component of ion gradient maintenance in the brain, is preferentially fueled by glycolytic ATP production over mitochondrial-generated ATP. 36 More efficient utilization of glucose for energy production could greatly benefit neurons in the ischemic penumbra, where blood flow has been significantly restricted but some energy substrates still reach the affected tissue. We observed that RPC also increases glycolytic rate under low glucose (25% of normal) and mitochondrial stress conditions, supporting a physiological relevance of these effects in ischemia. Consistent with these findings, resveratrol stimulates glycolytic ATP synthesis in yeast 37 as well as rodent liver 38 and has been shown to inhibit the pentose phosphate pathway. 39 Together, our findings illustrate a neuroprotective mechanism whereby RPC via neuronal SIRT1 promotes glycolytic efficiency to combat energetic stress. These results have far-reaching implications, as dysregulation of glycolysis plays a role in the pathogenesis and manifestation of Huntingtin disease, Alzheimer disease, and Parkinson disease, in all of which SIRT1 has a neuroprotective role. 40, 41 In terms of clinical efficacy, the translatability of resveratrol for the treatment of ischemic stroke is promising. It is safe for use in humans above the equivalent preconditioning doses, 42 desensitization to prolonged treatment does not occur 12 and protection has been validated from oral administration. 5 Moreover, it affords protection and recovery when administered postinjury. 5 A combination of prophylactic treatment, for the large population at risk for stroke, and treatment postinjury will likely prove a robust therapeutic strategy. Sirt1 is also an attractive therapeutic target with translational potential. Aside from resveratrol, recently developed SIRT1-specific activator compounds (SRT1720 and SRT2014) allow for direct, specific, and more robust activation of SIRT1, 43 making them ideal candidates for the induction of SIRT1-mediated neuroprotection.
